Table 1.

Metabolic characterization of STZ-treated mice

	Body weight (g)		Glucose (mg/dl)		Insulin (μg/dl)
	18 weeks (before STZ)	26 weeks (after STZ	18 weeks (before STZ)	26 weeks (after STZ)	18 weeks (before STZ)	26 weeks (after STZ)
Wt-Sham	27.96 ± 2.18	27.98 ± 2.03	149.99 ± 4.78	150.33 ± 4.78	0.63 ± 0.04	0.57 ± 0.01
Wt-STZ	29.27 ± 1.81	23.31 ± 2.06	135.22 ± 8.54	450.33 ± 41.95††	0.65 ± 0.04	0.23 ± 0.03††
APP/PS1-Sham	25.75 ± 1.98	25.08 ± 2.24	125.25 ± 10.02	123.57 ± 5.40	0.60 ± 0.02	0.56 ± 0.02
APP/PS1-STZ	28.50 ± 1.35	23.46 ± 1.37	125.50 ± 6.97	562.10 ± 21.10**	0.67 ± 0.03	0.23 ± 0.02††

No differences were detected in any of the parameters under study before administering STZ (18 weeks): body weight (p = 0.564), glucose (p = 0.234), and insulin (p = 0.518). Metabolic parameters were significantly affected at 26 weeks; after STZ treatment, glucose was increased in Wt-STZ mice, and even higher increases were observed in APP/PS1-STZ mice (**p < 0.01 vs. the rest of the groups, ††p < 0.01 vs. Wt-Sham and APP/PS1-Sham), insulin was significantly reduced in STZ-treated mice (††p < 0.01 vs. Wt-Sham and APP/PS1-Sham), and whereas body weight was slightly reduced in STZ-treated mice, differences did not reach statistical significance (p = 0.35). Data are representative of 6–11 mice and differences were detected by one-way ANOVA for independent samples followed by Tukey b or Tamhane tests as required